PDF(Pubmed)
Abstract：
This study assessed humoral and T cell-mediated immune responses to the BNT162b2 vaccine in orthotopic liver transplant (OLT) and lung transplant (LUT) recipients who received three doses of the vaccine from March 2021 at our institution. Serum samples were collected 60 days post-second and third dose to quantify antibodies against the spike region of SARS-CoV-2 while whole blood samples were collected to analyze the SARS-CoV-2-specific T-cell response using an IFN-γ ELISpot assay. We enrolled 244 OLT and 120 LUT recipients. The third dose increased antibody titres in OLT recipients (from a median value of 131 after the second dose to 5523 IU/mL, p < 0.001) and LUT recipients (from 14.8 to 1729 IU/mL, p < 0.001). T-cell response also increased in OLT recipients (from 8.5 to 23 IFN-γ SFU per 250,000 PBMC, p < 0.001) and LUT recipients (from 8 to 15 IFN-γ SFU per 250,000 PBMC, p < 0.001). A total of 128 breakthrough infections were observed: two (0.8%) OLT recipients were hospitalized due to COVID-19 and one died (0.4%); among LUT recipients, seven were hospitalized (5.8%) and two patients died (1.7%). In conclusion, the three-dose schedule of the BNT162b2 vaccine elicited both humoral and T cell-mediated responses in solid organ transplant recipients. The risk of severe COVID-19 post-vaccination was low in this population.
摘要：
这项研究评估了从2021年3月开始在我们机构接受三剂疫苗的原位肝移植（OLT）和肺移植（LUT）接受者对BNT162b2疫苗的体液和T细胞介导的免疫反应。在第二次和第三次给药后60天收集血清样品以定量针对SARS-CoV-2的刺突区域的抗体,同时收集全血样品以使用IFN-γELISpot测定法分析SARS-CoV-2特异性T细胞应答。我们注册了244个OLT和120个LUT收件人。第三剂量增加了OLT接受者的抗体滴度（从第二剂量后的中位数131到5523IU/mL，p<0.001）和LUT接受者（从14.8到1729IU/mL，p<0.001)。OLT受者的T细胞反应也增加（每250,000个PBMC从8.5到23个IFN-γSFU，p<0.001）和LUT接受者（每250,000个PBMC从8到15个IFN-γSFU，p<0.001)。共观察到128例突破性感染：2例(0.8%)OLT受者因COVID-19住院，1例死亡(0.4%)；在LUT受者中，7人住院(5.8%),2人死亡(1.7%).总之,BNT162b2疫苗的三剂量方案在实体器官移植受者中引起体液和T细胞介导的反应。在这一人群中，疫苗接种后严重COVID-19的风险很低。
